CN106632172A - 枸橼酸抗坏血酸铋钾及其制备方法和应用 - Google Patents
枸橼酸抗坏血酸铋钾及其制备方法和应用 Download PDFInfo
- Publication number
- CN106632172A CN106632172A CN201611237836.9A CN201611237836A CN106632172A CN 106632172 A CN106632172 A CN 106632172A CN 201611237836 A CN201611237836 A CN 201611237836A CN 106632172 A CN106632172 A CN 106632172A
- Authority
- CN
- China
- Prior art keywords
- ascorbic acid
- citric acid
- bismuth
- bismuth potassium
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 48
- YPQJHZKJHIBJAP-UHFFFAOYSA-N [K].[Bi] Chemical compound [K].[Bi] YPQJHZKJHIBJAP-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 21
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 21
- 229960005070 ascorbic acid Drugs 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 10
- 229910052797 bismuth Inorganic materials 0.000 claims abstract description 9
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910000416 bismuth oxide Inorganic materials 0.000 claims abstract description 8
- TYIXMATWDRGMPF-UHFFFAOYSA-N dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Bi+3].[Bi+3] TYIXMATWDRGMPF-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 7
- 239000011591 potassium Substances 0.000 claims abstract description 7
- HWDDAMXOXRDYMP-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OC(=O)CC(O)(C(O)=O)CC(O)=O HWDDAMXOXRDYMP-MGMRMFRLSA-N 0.000 claims description 31
- 239000001508 potassium citrate Substances 0.000 claims description 11
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(iii) oxide Chemical compound O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 claims description 8
- 229960002635 potassium citrate Drugs 0.000 claims description 7
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 7
- 235000011082 potassium citrates Nutrition 0.000 claims description 7
- 229960003975 potassium Drugs 0.000 claims description 6
- 229940036359 bismuth oxide Drugs 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 206010035664 Pneumonia Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 206010006451 bronchitis Diseases 0.000 abstract description 3
- 238000001816 cooling Methods 0.000 abstract description 3
- 208000006454 hepatitis Diseases 0.000 abstract description 3
- 231100000283 hepatitis Toxicity 0.000 abstract description 3
- 201000007270 liver cancer Diseases 0.000 abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3544—Organic compounds containing hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种新的物质枸橼酸抗坏血酸铋钾，其化学分子式为K3Bi2(C6H7O6)6(C6H5O7)·4H2O，分子量为1847.22。所述枸橼酸抗坏血酸铋钾的制备方法，包括以下步骤：(1)将氧化铋、抗坏血酸和枸橼酸钾投入反应容器，发生化学反应；(2)充分反应后，对产物进行烘干处理；(3)将烘干后的产物冷却至室温，得到产品枸橼酸抗坏血酸铋钾。本发明制备得到的枸橼酸抗坏血酸铋钾同时含钾、铋、抗坏血酸和枸橼酸，可用于制备胃药，用于治疗胃病、胃癌、感冒、支气管炎、哮喘、肺炎、肺癌、肝炎、肝癌、高血压等疾病。
Description
技术领域
本发明涉及生物化工医药食品领域，特别是涉及枸橼酸抗坏血酸铋钾及其制备方法和应用。
背景技术
钾K具有维持碳水化合物和蛋白质代谢、维持细胞内的正常渗透、维持神经肌肉的应激性和正常功能、维持心脏功能、维持细胞内外酸碱平衡和离子平衡以及降低血压等功能。铋Bi是铋剂类胃药中所含的元素。枸橼酸C6H8O7又名柠檬酸，是一种食品酸，其治疗胃病的药力弱。当今国内外市场上铋剂类胃药的发展停留在珠海丽珠试剂股份有限公司生产的枸橼酸铋钾K3Bi(C6H5O7)2上，但是该枸橼酸铋钾只能用于治疗普通胃病，不能用于治疗胃癌。
抗坏血酸C6H8O6(简称VC，又名维生素C)的主要作用是提高免疫力，预防癌症、心脏病、中风、保护牙齿和牙龈等。抗坏血酸具有的还原性可消除造成癌变的亚硝基和引起衰老的自由基，故有防衰老、抗癌、抗氧、抗坏血病、抗疲劳、消炎、消毒之功效，是优良的食品、调味品和饮品中的抗氧保鲜剂。抗坏血酸还是生物体主要的抗氧化剂，其功效是通过抗氧化作用而实现的。
当今国内外市场上少有同时含钾、铋、抗坏血酸和枸橼酸的药品，也未见枸橼酸抗坏血酸铋钾这一物质的相关报道。
发明内容
基于此，本发明的目的在于，提供枸橼酸抗坏血酸铋钾及其制备方法和应用，本发明的枸橼酸抗坏血酸铋钾同时含钾、铋、抗坏血酸和枸橼酸，可用于制备胃药，用于治疗胃病、胃癌、感冒、支气管炎、哮喘、肺炎、肺癌、肝炎、肝癌、高血压等疾病。
本发明由以下具体方案实现：
枸橼酸抗坏血酸铋钾，其化学分子式为K3Bi2(C6H7O6)6(C6H5O7)·4H2O，分子量为1847.22。
进一步地，所述的枸橼酸抗坏血酸铋钾，按质量百分比含钾6.35％，含铋22.63％，含抗坏血酸56.88％，含枸橼酸10.24％，含结晶水3.90％。
本发明的枸橼酸抗坏血酸铋钾，又名枸橼酸VC铋钾，经质谱确认和化学分析法测定，其化学分子式为K3Bi2(C6H7O6)6(C6H5O7)·4H2O，分子量为1847.22，按质量百分比含钾6.35％，含铋22.63％，含抗坏血酸56.88％，含枸橼酸10.24％，含结晶水3.90％，其纯度在99％以上(医药食品级)，为白色或微黄色结晶粉末，微溶于水。
本发明的枸橼酸抗坏血酸铋钾应用广泛，可用于治疗胃病、胃癌、感冒、支气管炎、哮喘、肺炎、肺癌、肝炎、肝癌、高血压等疾病，可制成片剂(每片0.2g，每次1-2片，一日三次服用)、冲剂或胶囊。
本发明的枸橼酸抗坏血酸铋钾的制备方法，包括以下步骤：
(1)将氧化铋、抗坏血酸和枸橼酸钾投入反应容器，进行化学反应；
(2)充分反应后，对产物进行烘干处理；
(3)将烘干后的产物冷却至室温，得到产品枸橼酸抗坏血酸铋钾。
本发明的制备方法简单、易操作，化学反应可在常温下进行，反应时间快。所述制备方法合成枸橼酸抗坏血酸铋钾的成本大致相当于氧化铋的价格，约为12万元/吨。
进一步地，所述步骤(1)的化学反应按以下化学反应式进行：
Bi2O3+6C6H8O6+K3C6H5O7·H2O＝K3Bi2(C6H7O6)6(C6H5O7)·4H2O。
进一步地，所述步骤(1)中，氧化铋、抗坏血酸与枸橼酸钾的摩尔比为1:6:1。
进一步地，所述步骤(1)的反应容器为搅拌球磨机，其为常用的研磨设备，固体氧化铋、抗坏血酸和枸橼酸钾能在搅拌球磨机中被研细、搅拌并发生固相化学反应生成枸橼酸抗坏血酸铋钾，不需要使用额外的溶剂，降低生产成本，同时减少产物的损失。
进一步地，所述步骤(1)的化学反应在常温下进行。
进一步地，所述步骤(1)的化学反应的反应时间为30～40min。
进一步地，所述步骤(2)的烘干处理在102～105℃温度下进行，能加快烘干效率，同时防止反应产物分解。
本发明所述的枸橼酸抗坏血酸铋钾可应用在医药食品领域。
为了更好地理解和实施，下面结合附图详细说明本发明。
附图说明
图1为本发明的枸橼酸抗坏血酸铋钾的制备方法流程图。
具体实施方式
请参阅图1，其是本发明的枸橼酸抗坏血酸铋钾的制备方法流程图。
实施例1
本实施例枸橼酸抗坏血酸铋钾的制备方法，包括以下步骤：
(1)称取原料氧化铋粉末466.0g、抗坏血酸粉末1056.7g和枸橼酸钾粉末324.4g，将原料投入搅拌球磨机中，启动搅拌球磨机，常温下进行化学反应，化学反应式为：
Bi2O3+6C6H8O6+K3C6H5O7·H2O＝K3Bi2(C6H7O6)6(C6H5O7)·4H2O。
(2)充分反应40min后，停止搅拌球磨机并放出产物，在105℃温度下对产物进行烘干处理；
(3)将烘干后的产物冷却至室温，冷却后称重，得到产品枸橼酸抗坏血酸铋钾1810.2g。
(4)将步骤(3)所得枸橼酸抗坏血酸铋钾包装成品。
实施例2
本实施例枸橼酸抗坏血酸铋钾的制备方法，包括以下步骤：
(1)称取原料氧化铋粉末233.0g、抗坏血酸粉末528.4g和枸橼酸钾粉末162.2g，将原料投入搅拌球磨机中，启动搅拌球磨机，常温下进行化学反应，化学反应式为：
Bi2O3+6C6H8O6+K3C6H5O7·H2O＝K3Bi2(C6H7O6)6(C6H5O7)·4H2O。
(2)充分反应30min后，停止搅拌球磨机并放出产物，在102℃温度下对产物进行烘干处理；
(3)将烘干后的产物冷却至室温，冷却后称重，得到产品枸橼酸抗坏血酸铋钾914.3g。
(4)将步骤(3)所得枸橼酸抗坏血酸铋钾包装成品。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。
Claims (10)
1.枸橼酸抗坏血酸铋钾，其化学分子式为K3Bi2(C6H7O6)6(C6H5O7)·4H2O，分子量为1847.22。
2.权利要求1所述的枸橼酸抗坏血酸铋钾，其特征在于：按质量百分比含钾6.35％，含铋22.63％，含抗坏血酸56.88％，含枸橼酸10.24％，含结晶水3.90％。
3.枸橼酸抗坏血酸铋钾的制备方法，包括以下步骤：
(1)将氧化铋、抗坏血酸和枸橼酸钾投入反应容器，进行化学反应；
(2)充分反应后，对产物进行烘干处理；
(3)将烘干后的产物冷却至室温，得到产品枸橼酸抗坏血酸铋钾。
4.根据权利要求3所述的枸橼酸抗坏血酸铋钾的制备方法，其特征在于：所述步骤(1)的化学反应按以下化学反应式进行：
Bi2O3+6C6H8O6+K3C6H5O7·H2O＝K3Bi2(C6H7O6)6(C6H5O7)·4H2O。
5.根据权利要求3或4任一项所述的枸橼酸抗坏血酸铋钾的制备方法，其特征在于：所述步骤(1)中，氧化铋、抗坏血酸与枸橼酸钾的摩尔比为1:6:1。
6.根据权利要求3或4任一项所述的枸橼酸抗坏血酸铋钾的制备方法，其特征在于：所述步骤(1)的反应容器为搅拌球磨机。
7.根据权利要求3或4任一项所述的枸橼酸抗坏血酸铋钾的制备方法，其特征在于：所述步骤(1)的化学反应在常温下进行。
8.根据权利要求3或4任一项所述的枸橼酸抗坏血酸铋钾的制备方法，其特征在于：所述步骤(1)的化学反应的反应时间为30～40min。
9.根据权利要求3或4任一项所述的枸橼酸抗坏血酸铋钾的制备方法，其特征在于：所述步骤(2)的烘干处理在102～105℃温度下进行。
10.权利要求1所述的枸橼酸抗坏血酸铋钾在医药食品领域的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611237836.9A CN106632172A (zh) | 2016-12-28 | 2016-12-28 | 枸橼酸抗坏血酸铋钾及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611237836.9A CN106632172A (zh) | 2016-12-28 | 2016-12-28 | 枸橼酸抗坏血酸铋钾及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106632172A true CN106632172A (zh) | 2017-05-10 |
Family
ID=58832078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611237836.9A Pending CN106632172A (zh) | 2016-12-28 | 2016-12-28 | 枸橼酸抗坏血酸铋钾及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106632172A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965382A (en) * | 1989-01-25 | 1990-10-23 | Eurosearch S.R.L. | Bismuth-containing compositions suitable for therapeutic use |
| CN103554070A (zh) * | 2013-11-08 | 2014-02-05 | 李玉成 | 抗坏血酸氧铋、其制备方法及应用 |
| CN104323004A (zh) * | 2014-10-30 | 2015-02-04 | 马辉 | 一种防治畜禽胃部疾病的饲料添加剂 |
-
2016
- 2016-12-28 CN CN201611237836.9A patent/CN106632172A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965382A (en) * | 1989-01-25 | 1990-10-23 | Eurosearch S.R.L. | Bismuth-containing compositions suitable for therapeutic use |
| CN103554070A (zh) * | 2013-11-08 | 2014-02-05 | 李玉成 | 抗坏血酸氧铋、其制备方法及应用 |
| CN104323004A (zh) * | 2014-10-30 | 2015-02-04 | 马辉 | 一种防治畜禽胃部疾病的饲料添加剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105410943B (zh) | 一种复合维生素片及其制备方法 | |
| CN103118689A (zh) | 含牛蒡子苷元的牛蒡子提取物及其制造方法 | |
| CN103896970B (zh) | 2-吡啶甲醇铜配合物及制备方法和应用 | |
| CN103739579A (zh) | 柠檬酸氢抗坏血酸钙及其制备方法和应用 | |
| CN105287511B (zh) | 土甘草a的应用 | |
| KR100923974B1 (ko) | 방사선을 이용한 지치 추출물의 생리활성 증진 방법 | |
| CN106632172A (zh) | 枸橼酸抗坏血酸铋钾及其制备方法和应用 | |
| US11021476B2 (en) | Pyrroloquinoline quinone monosodium and method for producing the same, and composition comprising the same | |
| EP2995605B1 (en) | Method for preparing a reduced coenzyme q10 powder. | |
| CN102885138A (zh) | 一种清醇畅心功能配方乳粉组合物及其制备方法 | |
| CN106924239A (zh) | 橙皮素用于制备防治糖尿病的药物的用途 | |
| CN106699782A (zh) | 柠檬酸抗坏血酸氢钙锌及其制备方法和应用 | |
| CN102070573B (zh) | 一种具有抗肿瘤活性的单四氢呋喃型番荔枝内酯化合物及其应用 | |
| KR20110018167A (ko) | 생리활성이 증가된 실크 펩타이드의 제조방법 및 그 방법에 의해 제조된 실크 펩타이드 | |
| CN105693793B (zh) | 一种利巴韦林化合物及其药物组合物 | |
| KR20220082583A (ko) | 기능성 벌사료 조성물 및 그 제조 방법 | |
| CN106699706A (zh) | 葡萄糖酸抗坏血酸钙及其制备方法和应用 | |
| CN103159710B (zh) | 用于抗病毒的十氢萘衍生物 | |
| CN106699705A (zh) | 山梨酸抗坏血酸五钙及其制备方法 | |
| CN106632207B (zh) | 一种高纯度gcg的制备方法 | |
| CN105685744A (zh) | 一种功能饮料 | |
| JP4847696B2 (ja) | マトリックスメタロプロテアーゼ阻害剤 | |
| CN106632174A (zh) | 牛磺酸抗坏血酸氢钙及其制备方法和应用 | |
| CN105254548A (zh) | 一种度骨化醇的纯化方法 | |
| CN106632173A (zh) | 硫酸氢抗坏血酸钾及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |